Tanenbaum B, Miett T, Patel SA. The emerging therapeutic landscape of relapsed/refractory multiple myeloma. Ann Hematol. 2023;102:1–11.

Article  PubMed  Google Scholar 

Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97:1086–107.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Engelhardt M, Kortum KM, Goldschmidt H, Merz M. Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible. Haematologica. 2024;109:2420–35.

CAS  PubMed  PubMed Central  Google Scholar 

Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33:2266–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Varughese P, Smith R, Xue M, Dorrow N, Hogea C, Maiese EM, et al. Real-world treatment patterns and outcomes of triple-class treated patients with multiple myeloma in the United States. Expert Rev Hematol. 2023;16:65–74.

Article  CAS  PubMed  Google Scholar 

Bhatt P, Kloock C, Comenzo R. Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse. Curr Oncol. 2023;30:2322–47.

Article  PubMed  PubMed Central  Google Scholar 

Morè S, Offidani M, Corvatta L, Petrucci MT, Fazio F. Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences. Cancers (Basel). 2023;15:2948.

Article  PubMed  Google Scholar 

Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123:3128–38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Montes de Oca R, Alavi AS, Vitali N, Bhattacharya S, Blackwell C, Patel K, et al. Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo. Mol Cancer Ther. 2021;20:1941–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baines AC, Ershler R, Kanapuru B, Xu Q, Shen G, Li L, et al. FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma. Clin Cancer Res : Off J Am Assoc Cancer Res. 2022;28:4629–33.

Article  CAS  Google Scholar 

Tzogani K, Penttilä K, Lähteenvuo J, Lapveteläinen T, Lopez Anglada L, Prieto C, et al. EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma. Oncologist. 2021;26:70–6.

NIH National Library of Medicine. ClinicalTrials.gov. A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody. https://clinicaltrials.gov/study/NCT03525678. Accessed 9 Oct 2024. 2024.

NIH National Library of Medicine. ClinicalTrials.gov. Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916. https://clinicaltrials.gov/study/NCT02064387. Accessed 9 Oct 2024. 2024.

Dimopoulos MA, Hungria VTM, Radinoff A, Delimpasi S, Mikala G, Masszi T, et al. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023;10:e801–e12.

Article  CAS  PubMed  Google Scholar 

US Food and Drug Administration. Announcement of the Revocation of the Biologics License for BLENREP. https://clinicaltrials.gov/study/NCT02064387. Accessed 9 Oct 2024. 2023.

European Medicines Agency. EMA recommends non-renewal of authorisation of multiple myeloma medicine Blenrep. https://www.ema.europa.eu/en/news/ema-recommends-non-renewal-authorisation-multiple-myeloma-medicine-blenrep. Accessed 9 Oct 2024. 2023.

Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, et al. Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma. N. Engl J Med. 2024;391:408–21.

Article  CAS  PubMed  Google Scholar 

Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, et al. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma. N. Engl J Med. 2024;391:393–407.

Article  CAS  PubMed  Google Scholar 

Offidani M, Corvatta L, Morè S, Olivieri A. Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety. Drug Des Devel Ther. 2021;15:2401–15.

Article  PubMed  PubMed Central  Google Scholar 

Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 2015;7:1187–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34:985–1005.

Article  PubMed  Google Scholar 

Ferron-Brady G, Rathi C, Collins J, Struemper H, Opalinska J, Visser S, et al. Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma. Clin Pharm Ther. 2021;110:1282–92.

Article  CAS  Google Scholar 

Cortes-Selva D, Perova T, Skerget S, Vishwamitra D, Stein S, Boominathan R, et al. Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study. Blood. 2024;144:615–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N. Engl J Med. 2021;384:705–16.

Article  CAS  PubMed  Google Scholar 

Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023;29:2295–306.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rathi C, Collins J, Struemper H, Opalinska J, Jewell RC, Ferron-Brady G. Population pharmacokinetics of belantamab mafodotin, a BCMA-targeting agent in patients with relapsed/refractory multiple myeloma. CPT Pharmacomet Syst Pharm. 2021;10:851–63.

Article  CAS  Google Scholar 

Nooka AK, Cohen AD, Lee HC, Badros A, Suvannasankha A, Callander N, et al. Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial. Cancer. 2023;129:3746–60.

Article  CAS  PubMed  Google Scholar 

Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21:207–21.

Article  CAS  PubMed  Google Scholar 

Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia. 2022;36:1371–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, et al. Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J. 2019;9:37.

Article  PubMed  PubMed Central  Google Scholar 

Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, et al. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018;19:1641–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hungria V, Weisel K, Radinoff A, Delimpasi S, Mikala G, Masszi T, et al. Updated results from DREAMM-3, a phase 3 study of belantamab mafodotin (Belamaf) versus pomalidomide plus dexamethasone in patients (pts) with relapsed/refractory multiple myeloma (RRMM). Int Myeloma Soc. 25–28 September 2024; Riocentro, Rio De Janeiro, Brazil 2024.

Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394:2096–107.

Article  CAS  PubMed  Google Scholar 

Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N. Engl J Med. 2016;375:1319–31.

Article  CAS